An international scientific competition widely credited with spurring the development of artificial intelligence (AI) for biology appears to be on its deathbed. Known as the Critical Assessment of protein Structure Prediction (CASP), the 3-decade-old competition has run out of funding from the U.S. National Institutes of Health (NIH) and will exhaust emergency support from the University of California (UC) Davis, which oversees the grant, on 8 August. UC Davis has told the two researchers who run the program that their jobs will end in weeks.
NIH officials have offered no reassurance about the program’s future, despite repeated inquiries from CASP organizers, who submitted a request to renew their $800,000 grant last year. The agency did not respond to multiple requests for comment. John Moult, a CASP co-founder at the University of Maryland, says contest organizers are “scrambling” to find alternative funding from foundations and other countries.
If CASP disappears, “it would be a tremendous loss for the community,” says Jianlin Cheng, a protein modeler at the University of Missouri. “CASP is the most successful and prestigious scientific competition in the world.” Not only did it fuel the creation of AI programs such as RosettaFold and Google DeepMind’s AlphaFold, whose developers shared in last year’s Nobel Prize in Chemistry, but CASP has evolved to host new competitions, such as determining how drug molecules bind with protein targets, a key to discovering new medicines. “CASP continues to have a major impact on a wide range of scientific fields,” Cheng says.
Started in 1994, the biennial CASP competition began as a way to independently evaluate computer models aimed at solving the so-called protein folding problem: predicting how long linear chains of amino acids assemble into the 3D shapes required for their function. At the time, research teams developing the models were regularly claiming breakthroughs. “Everybody thinks their method is the greatest. That’s just the way people are,” says Nick Grishin, a biochemist at the University of Texas, Southwestern. CASP’s goal was to compare the methods head to head, he adds. “When the methods are stacked against one another they see where the failures are and that’s what drives science forward.”
Moult and his colleagues began by asking experimental groups which protein structures they expected to solve soon, using x-ray crystallography or other direct measures. They then invited computer modelers to predict the same structures, and had independent experts compare the models with the finished experimental data. In CASP1, modelers’ predictions for the most challenging class of proteins were “near random,” Moult says.
But in CASP14 in 2020, the year RosettaFold and AlphaFold burst on the scene, bringing a dramatic jump in accuracy in structure prediction. In last year’s CASP16, modelers achieved a nearly 95% success rate with the most difficult proteins. “The problem of folding single proteins is nearly solved,” concludes a 2 June preprint by Grishin and his colleagues summarizing the most recent CASP16 results.
“That’s a tremendous achievement,” Grishin says. “But what lies ahead is even more important.” Biochemistry, he notes, works through molecular interactions: proteins with other proteins, and proteins with DNA, RNA, and small molecules. Because those pairings are hard to study in the lab, there is less experimental data available for training AIs to predict the structures that result. As a result, the models struggle. In CASP16, for example, AlphaFold3—an AI designed to predict structures of protein complexes—hit the mark in only 52.5% of test cases, and even that was considered an impressive jump over previous efforts.
As protein models have improved, CASP organizers have come up with new ways to challenge the modelers, says its director, Krzysztof Fidelis, who got his 45-day notice from UC Davis last week. In last year’s CASP 16, 209 modeling groups worldwide tried to solve not only the structure of individual proteins, but also the 3D structures of RNA molecules, ensembles of proteins, molecules such as drugs bound to proteins, and the variety of shapes that so-called disordered proteins can adopt. “Every CASP is essentially a new set of competitions,” says Andriy Kryshtafovych, a mathematician who helps run the UC Davis program and has also been given a termination notice.
In addition to paying the salaries of Kryshtafovych and Fidelis, the UC Davis grant funds the coordination of legions of scientific volunteers, including hundreds of experimental groups that come up with targets, panels that decide the foci of each competition, modeling groups, assessors, and a conference after every competition to announce the winners and share lessons on what worked. “There’s a lot of leverage of the investment,” Moult says.
Organizers still hold out hope CASP’s grant might be renewed. NIH has been slow to spend its 2025 budget under President Donald Trump’s administration, stoking fears that much of the agency’s $48 billion in funding for this fiscal year will go unused. CASP might simply be caught in the slowdown.
In case NIH or an alternative funder doesn’t come through, Moult and others say UC Davis is currently exploring whether it can afford to archive CASP’s computer servers. That way the competition’s decades of resources won’t be lost. But even if the money does come through, there is no guarantee CASP’s success will endure after those running the program have moved on and the network of scientific volunteers has disbanded. Says Kryshtafovych: “It will not be easy to reconstruct this.”